Brexit must not disrupt drug R&D, say pharma chiefs - (Financial Times via NewsPoints Desk)

  • Pharmaceutical industry executives warned that the UK's plan to leave the EU cannot be allowed the affect drug development, Financial Times reported Friday.

  • Industry representatives noted that more than 200 hours of meetings have taken place over the last year, including organisations such as the Association of the British Pharmaceutical Industry, the BioIndustry Association and European Federation of Pharmaceutical Industries and Associations.

  • Drugmakers involved in the meeting included AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis, Pfizer, Roche, Sanofi and Takeda.

  • In a letter delivered to UK health secretary Jeremy Hunt and business secretary Greg Clark, the executives said it is "critical for the UK and the EU to recognise that patient safety and public health throughout Europe rely on the current pan-European regulations and standards applying to the research, development, manufacture and supply of medicines."

  • The executives indicated that they were pleased by Hunt and Clark's commitment "to seek future alignment with the current EU regulatory framework and harness our collective strength within the UK and the EU," adding that this approach was "in the best interests for business and patients Europe-wide [and globally]."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles